Crawford M H, Ludden T M, Kennedy G T, Sodums M T, O'Rourke R A, Amon K W
Clin Pharmacol Ther. 1982 Apr;31(4):459-65. doi: 10.1038/clpt.1982.60.
In six normal subjects and 6 patients with primary cardiomyopathy, left ventricular performance was evaluated at rest and during isometric handgrip exercise after 4 days of oral N-acetylprocainamide (NAPA) at each of the three dosage levels (3, 4, 5, and 6 gm/day). Changes in heart rate, blood pressure, and echocardiographic performance indices were noted during isometric exercise, but no effect of NAPA could be demonstrated. In five additional patients with ventricular dysrhythmias due to cardiac diseases, NAPA was given by vein until dysrhythmias were controlled and then a maintenance infusion was continued for 48 hr. Continuous ECG recordings showed excellent dysrhythmia control in four of the five patients, but no effect of NAPA on heart rate, blood pressure, mean pulmonary artery pressure, mean pulmonary artery wedge pressure, or cardiac output was demonstrated, either at the peak of initial infusion (serm NAPA 27 +/- 6.7 microgramsm/ml) or at steady state during the maintenance infusion (16 +/- 4.5 microgramm/ml). We conclude that NAPA by vein and mouth in clinically appropriate doses should be safe in patients with the reduced left ventricular performance due to cardiac disease.
在6名正常受试者和6名原发性心肌病患者中，在口服三种剂量水平（3、4、5和6克/天）的N - 乙酰普鲁卡因胺（NAPA）4天后，于静息状态和等长握力运动期间评估左心室功能。在等长运动期间记录心率、血压和超声心动图性能指标的变化，但未发现NAPA有任何作用。在另外5名因心脏病导致室性心律失常的患者中，静脉给予NAPA直至心律失常得到控制，然后持续维持输注48小时。连续心电图记录显示，5名患者中有4名心律失常得到了良好控制，但无论是在初始输注峰值（血清NAPA 27±6.7微克/毫升）还是在维持输注稳态时（16±4.5微克/毫升），均未发现NAPA对心率、血压、平均肺动脉压、平均肺动脉楔压或心输出量有任何影响。我们得出结论，对于因心脏病导致左心室功能降低的患者，静脉和口服临床适当剂量的NAPA应该是安全的。
